SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX

SIGA TECHNOLOGIES INC

FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.
Q4 2021 revenues $115.4M ($73.2M net income, $0.98 EPS) driven by $113M U.S. delivery of oral TPOXX.
International product sales $13M in 2021, up from $2M; EMA approved oral TPOXX in Jan 2022, Health Canada in Dec 2021.
SIGA repurchased ~3.8M shares for $26M in 2021 (~5% of shares outstanding); collaboration with Bioarchitech on immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.